OTC Athlete’s Foot Drug Labeling Changes Supported By NDAC Panel, Industry
This article was originally published in The Tan Sheet
Executive Summary
Current labeling for OTC drugs for Tinea pedis (athlete's foot) may mislead consumers toward greater expectations of benefit and should be changed, FDA's Nonprescription Drugs and Dermatologic and Ophthalmic Drugs advisory committees agreed unanimously at a May 6 meeting in Rockville, Md
You may also be interested in...
NDAC’s busy schedule
A two-day joint meeting of the Nonprescription and Dermatologic & Ophthalmic Drugs Advisory Committees is scheduled for March 24-25. The two committees discussed labeling issues for OTC athlete's foot drugs during a meeting in May (1"The Tan Sheet," May 10, 2004, p. 10). NDAC also is scheduled to meet with the Endocrinologic & Metabolic Drugs Advisory Committee Jan. 13-14...
NDAC’s busy schedule
A two-day joint meeting of the Nonprescription and Dermatologic & Ophthalmic Drugs Advisory Committees is scheduled for March 24-25. The two committees discussed labeling issues for OTC athlete's foot drugs during a meeting in May (1"The Tan Sheet," May 10, 2004, p. 10). NDAC also is scheduled to meet with the Endocrinologic & Metabolic Drugs Advisory Committee Jan. 13-14...
NDAC’s busy schedule
A two-day joint meeting of the Nonprescription and Dermatologic & Ophthalmic Drugs Advisory Committees is scheduled for March 24-25. The two committees discussed labeling issues for OTC athlete's foot drugs during a meeting in May (1"The Tan Sheet," May 10, 2004, p. 10). NDAC also is scheduled to meet with the Endocrinologic & Metabolic Drugs Advisory Committee Jan. 13-14...